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ndovascular thrombectomy is highly effective for the treatment of acute ischemic stroke because of proximal large vessel occlusion, 1 but the treatment effect falls rapidly with time. 2 Almost all patients with severe stroke are transported by an emergency medical service (EMS), which is independently associated with reduced time to treatment. 3 Nevertheless, delays are frequent in patients arriving for endovascular thrombectomy via secondary transport from another facility. 1 To reduce time to treatment, some jurisdictions are exploring redirect policies, whereby patients bypass a closer primary stroke center and are instead transported directly to endovascular-capable facilities. 4 Instituting a pathway for hospital bypass is a complex undertaking that involves the coordination of diverse stakeholders. 4 Core components include patient selection criteria, interfacility agreements (eg, transfer and repatriation), paramedic training, and outcome evaluation. Approaches to patient selection have drawn recent interest, particularly in the use of simplified standardized clinical examinations for the diagnosis of proximal large vessel occlusion. In this review, we review current clinical and technological approaches to patient selection and discuss implementation in the context of jurisdictional features. The database search terms for this review article are provided in the online-only Data Supplement.
Diagnosis: Foundation for Triage
Proximal large vessel occlusion is the substrate for endovascular thrombectomy-field diagnosis of large vessel occlusion is the sine qua non for hospital bypass. In this section, we discuss important caveats in prehospital diagnosis and follow with a review of specific clinical and technological approaches.
Caveats
Three caveats apply to the interpretation of studies of diagnostic tests for transport decision making: First, diagnosis is primarily a means to support transport decision making, not an end. If 2 diagnoses share the same transport destination, then it might not be so important to distinguish between them. For example, distinguishing between intracerebral hemorrhage (ICH) and large vessel occlusion may be of little practical value if either would be transferred to a comprehensive center for advanced care. This pragmatic perspective is easy to overlook if singularly focused on the usual benchmark of diagnostic accuracy. Second, if the objective of transport decision making is to identify treatment candidates, it must be emphasized that diagnosis alone does not establish eligibility.
Other factors, such as deficit severity, premorbid function, or the extent of ischemic injury, contribute to treatment decision making. Considering diagnostic and eligibility factors together may improve the specificity of selection criteria over diagnosis alone. Finally, the distinction between proximal and nonproximal large vessel occlusion is arbitrary. The classification of M1-middle cerebral artery and terminal internal carotid artery occlusions is not controversial, but the desirable classification of M2-middle cerebral artery occlusions is uncertain. Ideally, equipoise for this anatomic boundary would be recognized in the development and evaluation of diagnostic strategies.
Standardized Clinical Examinations (Field Tests)
Standardized clinical examinations are an attractive option because they require no capital investment. They should also be easy to implement because examination-based triage is already routine for the transport of patients to primary stroke centers. Development and validation of such scales have been a focus of recent research, with at least 9 candidate scales proposed thus far. All scales share a similar focus on clinical signs but differ with respect to the domains assessed, design characteristics, and supporting evidence (Table 1) .
Readers contemplating this body of literature likely share one pressing concern-which scale is most accurate for the diagnosis of large vessel occlusion? This question will be best resolved on the basis of randomized controlled studies in the prehospital environment (eg, RACECAT [Direct Transfer to an Endovascular Center Compared to Transfer to the Closest Stroke Center in Acute Stroke Patients With Suspected Large Vessel Occlusion], clinicaltrials.gov registration NCT02795962). Methods used in most of the available observational studies limit generalizable assessment of scale accuracy. Confident assessment of accuracy requires that several conditions be met: (1) EMS-ready scale method; (2) study population representative of suspected stroke, including patients with ICH; and (3) prospective validation in the prehospital setting. Only Rapid Arterial Occlusion Evaluation scale (RACE) has met all 3 conditions, and many scales fail to meet any.
EMS-ready methods are important to ensure that the scale can be performed as intended in the field. Published EMSspecific instructions represent a fair minimum standard. The Los Angeles Motor Scale has been successfully implemented in many jurisdictions, 5 supporting a de facto claim for readiness. Although RACE 6 and Cincinnati Stroke Triage Assessment Tool 7 have only been each implemented in a single jurisdiction, they include simplified instructions that seem appropriate for paramedic use. The app-based implementation of Field Assessment Stroke Triage for Emergency Destination (FAST-ED) includes simplified instructions, but it is unclear whether these have been validated (eg, published FAST-ED criteria for neglect include extinction to double simultaneous stimuli, 8 but the app does not provide a corresponding instruction). 9 EMS readiness of methods for the remaining scales is not established. Techniques for vision, aphasia, neglect assessment are nonlinear, and grading criteria suggest an unachievable standard. For example, criteria for vision include 4-quadrant fields, diplopia, and ocular alignment. 10 The remaining scales implicitly rely on National Institutes of Health Stroke Scale (NIHSS) techniques, some of which may be too complex to apply to the field. For example, NIHSS gaze includes observation of spontaneous eye movements, horizontal pursuit, and performance of the oculocephalic maneuver. Simplified techniques have been proposed by others, such as the use of a shoulder tap to evaluate for gaze palsy, 11 but agreement with NIHSS equivalents cannot be assumed.
A study population composed of patients with representative disease conditions is necessary to ensure that estimates of sensitivity and specificity are valid. Validation of a diagnostic test against a highly selected population creates risk of spectrum bias. 12 In the context of stroke screening tests, patients with large vessel occlusion should be compared with patients with all other causes of the acute stroke syndrome: ischemic stroke without large vessel occlusion, ICH, and stroke mimicking conditions. However, most studies systematically excluded patients with ICH, either by relying on databases of patients with ischemic stroke (Cincinnati Stroke Triage Assessment Tool, 13 Los Angeles Motor Scale, 14 FAST-ED, 8 gaze, face, arm speech, 15 Prehospital Acute Stroke Severity Scale 16 ) or by excluding patients without vascular imaging from key analyses (3-item stroke scale, 17 vision, aphasia, neglect 10 ). The resulting estimates of sensitivity and specificity are likely to be biased because ICH is likely to present with a severe stroke phenotype similar to large vessel occlusion.
Prospective validation in the prehospital setting affords greatest confidence in the assessment of scale accuracy. First, it increases the likelihood of capturing a truly representative population. Second, it ensures that the scales are performed by paramedics under representative testing conditions. It is likely that scales administered by highly trained and experienced study staff will be more reliable than scales administered by paramedics with less training and infrequent exposure to stroke. Adverse conditions of the prehospital setting, including time pressure, may also detract from scale reliability. To date, only RACE has been subject to rigorous prospective validation. 6 A prospective study of Cincinnati Stroke Triage Assessment Tool 7 is limited by study number (n=58), precluding meaningful assessment of accuracy. Although prospective in design, the vision, aphasia, neglect was administered by registered nurses at the time of hospital triage. 10 All other scales have been validated using retrospective hospital-based assessments by trained study staff.
In summary, evidentiary support is strongest for RACE. Although it has not been independently validated in a second prospective study, its postimplementation performance has Where stated, accuracy of NIHSS is included to highlight challenges in cross-study comparison (most scales compare favorably to the NIHSS in their respective study). 3-IS indicates 3-item stroke scale; AUC, area under receiver-operator curve; C-STAT, Cincinnati Stroke Triage Assessment Tool; EMS, emergency medical service; FAST-ED, Field Assessment Stroke Triage for Emergency Destination; G-FAST, gaze, face, arm speech; ICH, intracerebral hemorrhage; LAMS, Los Angeles Motor Scale; LOC, level of consciousness; NIHSS-8, National Institutes of Health Stroke Scale 8-item version; n.r., not reported; PASS, Prehospital Acute Stroke Severity Scale; RACE, Rapid Arterial Occlusion Evaluation; and VAN, vision, aphasia, neglect.
*Pilot prospective paramedic data. †Simplified instructions provided in training video.
Stroke

April 2018
reportedly proven satisfactory. 18 Los Angeles Motor Scale and Cincinnati Stroke Triage Assessment Tool are both supported by an EMS-ready method, but nonrepresentative study populations limit confidence in the reported accuracy of the scales for the diagnosis of large vessel occlusion. Interpretation of evidence for the remaining scales is limited by nonrepresentative populations and by the use of scale methods that might not be reproducible in the prehospital setting. Implementation of these scales would require the ad hoc development of appropriate examination techniques, which would be of uncertain reliability and validity.
Despite relatively strong evidentiary support, enthusiasm for RACE has been tempered by the perceived complexity of the scale. Most of the other scales have been specifically developed as simplified alternatives. In general, evidence supports a more limited emphasis on motor, gaze, and level of consciousness. Post hoc analysis of the RACE scale suggests small incremental gains in accuracy from the assessment of aphasia and agnosia/neglect. These domains are also de-emphasized in most of the scales developed retrospectively, with the exception of FAST-ED and gaze, face, arm speech (gaze, face, arm speech is a special case because the FAST component is specified a priori). 15 The importance of other cortical domains, such as aphasia or neglect, may be heightened if the diagnosis of M2-middle cerebral artery occlusions becomes a priority.
Even the most complex assessments, such as the full scale NIHSS, have limited accuracy for the diagnosis of large vessel occlusion. Understanding the reasons for falsepositive and false-negative classification may yield insights useful for future scale refinement. As an example, consider the diagnostic classifications for RACE, illustrated in the Figure. Most false-positive errors are attributable to 2 groups: ICH and ischemic stroke without large vessel occlusion. Strategies to specifically identify intracranial hemorrhage seem likely to reduce the false-positive rate. Reasons for misclassification of ischemic stroke are uncertain; interpretation would be aided by more precise classification based on occlusion site (eg, small vessel versus nonproximal large artery). It is likely that some false-positive errors include M2-middle cerebral artery occlusions amenable to endovascular thrombectomy, and the desirable classification of these patients is debatable. False-negative errors are infrequent, and the rarity of subsequent endovascular treatment suggests that some might represent mild presentations that are too mild to treat. Nevertheless, given the high risk of progressive deficit associated with large artery occlusion, emergency vascular imaging must still be considered as mandatory in patients with negative clinical screens. 19 Further gains in diagnostic accuracy are conceivable on 2 fronts: (1) clinical markers for ICH, and (2) point of care diagnostic tools. Clinical tools have achieved fair accuracy by identifying characteristic features of hemorrhage, such as headache, 20 emesis, 20, 21 severe hypertension, 20, 22, 23 and depressed level of consciousness. 20, 22, 24 Distinguishing ICH from ischemia may allow for the advent of prehospital ICH-focused treatment, including field administration of antihypertensives. Interest in this area may now re-emerge. Well-resourced jurisdictions may additionally consider the use of point of care technology, as reviewed in the next section.
Point of Care Diagnostic Technologies
Technological aids to the diagnosis of large vessel occlusion or ICH may contribute to, or supplant, the use of clinical examination for stroke transport decision making. In this section, we will discuss evidence for and potential applications of blood-based biomarkers, near-infrared spectroscopy, transcranial Doppler, and mobile computed tomography (CT)/CT angiography.
Blood-Based Biomarkers
There are currently no accurate blood-based biomarkers for the diagnosis of acute ischemic stroke. 25 It seems unlikely that any blood-based biomarker could distinguish ischemic stroke on the basis of occlusion site given similar underlying pathophysiology. However, biochemical discrimination of ischemic stroke from ICH is plausible. In particular, glial fibrillary acidic protein may prove useful for the early diagnosis of larger ICHs. Systematic review of 4 studies demonstrated sensitivity 0.72 to 0.88 and specificity 0.94 to 0.98 within 6 hours of onset. 26 At a threshold of 0.29 ng/mL, glial fibrillary acidic protein accurately classified 9/25 ICH and 49/49 ischemic stroke at the time of first medical contact (median 62 minutes onset to blood test). 27 True positive rate was higher in patients with ICH volume >15 mL. This suggests that the test may help to identify patients with severe deficits because of cortically-based hemorrhages but may misclassify patients with severe deficits because of smallvolume hemorrhages in eloquent areas, such as the posterior limb of the internal capsule. A role for blood-based biomarkers in hospital triage has yet to be established but may emerge for the identification of large-volume ICH mimicking large vessel occlusion. 
Near-Infrared Spectroscopy
Near-infrared wavelengths can penetrate bone and soft tissue to a depth of several centimeters. Blood is characteristically highly absorbent within the near-infrared spectrum and can be identified using near-infrared spectroscopy. Handheld spectrophotometers can reliably diagnose modest, superficial hemorrhages (>3.5 mL and <2.5 cm from brain surface). 28 However, lack of sensitivity to deeper hemorrhage will preclude application to stroke triage.
Transcranial Doppler
Transcranial Doppler has high sensitivity for the diagnosis of proximal large vessel occlusion. It also has high sensitivity for ICH [29] [30] [31] but with no precedent for use in thrombolysis decision making. Imaging is not possible in ≈10% of patients because of limited temporal bone windows. 32 Equipment cost is cited as a major barrier to prehospital use. 33 Operating expenses are also likely to be a barrier as image acquisition requires an on-scene technologist with specialized training. Acquisition guided by a remote expert is possible, but resulting study times of 30 to 55 minutes are likely unfeasible. 34 Machine-guided acquisition is a promising approach 35, 36 but has not been demonstrated for the prehospital setting. At least 1 jurisdiction has used an on-scene expert for image acquisition, 37 but the long-term feasibility and cost effectiveness of this approach are uncertain.
Mobile CT Technology: Cone Beam CT and Multidetector CT
CT-based techniques are standard for the diagnosis of ischemic stroke and for determining eligibility for both thrombolysis and mechanical thrombectomy. Image quality on mobile platforms is adequate for the diagnosis of stroke, including evaluation for early ischemic changes. 38 Angiographic and perfusion studies are technologically feasible 39 but have not been systematically compared with fixed-unit imaging. At least 1 unit has been equipped with a mobile gantry, permitting arch-to-vertex imaging. Because these techniques offer certain assessment of treatment eligibility, they permit immediate administration of tissue-type plasminogen activator and concurrent activation of the endovascular team. This will allow for substantial reduction in time to thrombolysis and endovascular treatment. Cone beam CT technology with flat panel detector has the potential to provide a lower cost mobile solution with the added advantages of a smaller footprint and open adaptable geometry. However, current technology experience from poor image quality because of artifacts and noise, and further innovation is required. 40 Cost and feasibility are major barriers to deployment of mobile CT/CT angiography. The first mobile CT deployment in Saarland, Germany, was estimated to be cost effective based on an annual operating cost of €169 803 ($USD 208 629) and an estimated direct cost savings of €17 872 ($USD 21 958). 41 The authors estimate an additional 5% of patients would have a favorable outcome with mobile stroke unit treatment versus conventional care. However, cost effectiveness has not been demonstrated on the basis of actual patient-level expenditures nor has it been proven for the North American environment.
Given the substantial capital investment required to launch a mobile CT program, it is reasonable for jurisdictions with limited resources to wait for the results of further study.
Beyond Diagnosis: Consideration of Eligibility
The rationale for selecting patients for hospital bypass is to facilitate rapid endovascular treatment without overwhelming treatment sites. Efficient patient selection requires consideration of treatment eligibility, which is only partially determined by the diagnosis of large vessel occlusion. Other factors, such as extent of ischemic injury, premorbid function, and the severity of the clinical deficit, are also relevant.
Of the assessment strategies discussed thus far, only RACE has been assessed from the perspective of treatment eligibility. The results are disappointing: at a cut-value of ≥5, the scale had 42% positive predictive value for the diagnosis of large vessel occlusion, but only 19% positive predictive value for treatment with thrombectomy. 6 Although this study was conducted before release of the endovascular treatment trials, historical practice patterns have not dramatically changed to explain this low treatment rate. If replicable, this result suggests that increasing test positive predictive value will require specific strategies to predict treatment eligibility.
In contrast to the extensive work that has been done on assessment for diagnosis, we are aware of no systematic research that has attempted to identify prehospital factors predicting endovascular eligibility. Ischemic time is an obvious factor but has not been systematically evaluated against eligibility in population-based samples. 42 Trial-based inclusion/ exclusion criteria have been applied as substitutes but without knowledge of specificity at threshold values. This approach of convenience will likely be complicated by findings from recent extended time-window trials, including DAWN (Clinical Mismatch in the Triage of Wake Up and Late Presenting Strokes Undergoing Neurointervention With Trevo) 43 and DEFUSE-3 (Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3). 44 Empirical study will also allow consideration of alternative time-based concepts, such as time symptom first observed, that may prove superior to time last seen well for predicting endovascular eligibility.
Incorporation of eligibility factors, such as time, would permit greater nuance in the interpretation of diagnostic predictions. For example, it is likely reasonable to defer bypass for a patient with marginal likelihood of large vessel occlusion if they are also marginal in terms of time from onset. Nor must eligibility be restricted to consideration of thrombectomy. Assessment of eligibility for other treatments, such as intravenous thrombolysis, may also enhance decision making. For example, a patient with medical contraindications to thrombolysis, such as active anticoagulant use, may benefit from bypass even if the likelihood of large vessel occlusion is marginal.
Development of eligibility-based criteria for hospital bypass is currently hindered by a lack of data. Future research should address population-level clinical determinants for eligibility, as well as the investigation of novel predictors, such as a biomarker for established infarct. Standard definitions for eligibility will be required to ensure validity and to facilitate cross-study comparison. Robust strategies will be needed to mitigate risk of bias
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because of missing data (eg, patients who do not undergo vascular imaging) and self-fulfilling prophecy (eg, transport destination influences likelihood of receiving endovascular treatment).
Managing Complexity: Supports for Decision Making
Optimal assessment for hospital bypass may require consideration of multiple factors. Even straightforward clinical examinations may be difficult for paramedics to master given constraints on initial training, 45 infrequent exposure, and limited feedback. 46 In a population-based study of paramedic dispatches in Nara prefecture, Japan, only 1.9% of calls were for stroke. 47 Adding additional layers of complexity, such as varying examination-and time-based thresholds for endovascular versus thrombolysis transfer, may prove overwhelming. Specific supports to complex decision making may extend the capabilities of paramedics for stroke triage.
Online Medical Control
Online medical control refers to real-time physician involvement in prehospital care, usually via telephone or radio. Physicians provide transport and treatment recommendations on the basis of information gathered on scene. Application to decision making for thrombectomy has not been evaluated, but it is likely applicable to the assessment of both diagnosis and treatment eligibility. Benefit of online medical control for diagnosis may be surmised from the FAST-MAG trial (Field Administration of Stroke Therapy -Magnesium), which achieved high specificity in prehospital diagnosis of stroke through field communication with stroke specialists. 48 Diagnostic accuracy might be further enhanced via remote examination over an audio-video link. Remote administration of the NIHSS is feasible with low-cost consumer mobile technology platforms and yields high agreement compared with in-person assessment. 49 It is reasonable to expect that the resulting accuracy for large vessel occlusion would be comparable to the accuracy of an in-hospital evaluation and will likely exceed the accuracy of reduced clinical scales such as Los Angeles Motor Scale or RACE.
Beyond diagnosis, physician judgment also facilitates consideration of eligibility factors, such as premorbid function. Online medical control increases the accuracy of the time last seen well determination, thereby reducing the number of false-positive transfers for thrombolysis. 50 It allows the potential consequences of delayed thrombolysis versus delayed thrombectomy to be considered in the context of the patient presentation and anticipated transport and treatment times. It is a necessary step in the dispatch of flight resources, which may reduce time to treatment in geographically dispersed locations. Finally, it permits the preparation of the receiving site, potentially including notification of endovascular team members.
The major drawback of online medical control is disruption to paramedic patient care and to physician activities. One strategy to reduce such disruption is to use a screen-andconsult method to reduce the number of calls for low likelihood cases. False-positive calls will still generate concern, but this should be tempered by recognition of avoided call-ins. An observational study of this strategy is underway for rural locales in our jurisdiction. 51 
Clinical Decision Support Systems
Clinical decision support systems are technologies or tools that facilitate decision making by guiding data collection and analysis. It is most commonly used to refer to specific functions in an electronic health record but can also include paper-based tools, such as standard order sets or documentation templates. Simple implementations for stroke may take the form of quick-reference cards. More complex implementations may model some of the functions of online medical control and require technology. Complex organization of emergency medical systems and widespread use of proprietary technology have likely slowed development in this area. This is likely to change with ubiquitous low-cost app-based mobile platforms. These platforms offer major advantages in this context: low cost of development, option for deployment along parallel proprietary systems, and rapid propagation of practice changes through automatic updates. One group has already released one such app that guides the FAST-ED examination, collects eligibility data, and provides a transport recommendation in the context of travel times to treatment sites. 9 Although evidence for decision-making choices made by the app is lacking, the application provides proof of concept for future work.
Implementation: Relevance of Jurisdictional Features
In this review, we have discussed clinical and technological approaches to the diagnosis of large vessel occlusion (Table 2) , introduced consideration of other eligibility factors, and described approaches to the management of decisionmaking complexity. In this final section, we will explore the relevance of jurisdictional features to implementation of hospital bypass.
Parameters for transport decision making should account for the probable consequences of overtriage or undertriage, which are largely determined by jurisdictional features (Table 3) . Estimating the overall impact of triage error is difficult on account of (1) asymmetry of consequences between actors, (2) mitigating or exacerbating effects of jurisdictional features, and (3) uncertainty estimates of harm. Ambiguity in the definition of overtriage and undertriage clouds matters further-is it overtriage to send a patient with established large artery stroke to a comprehensive site or is it undertriage to send them to a primary? Although difficult, some determination of the relative harm of falsepositive versus false-negative errors is necessary to guide decision making.
Requirements for sensitivity or specificity should be chosen on the basis of jurisdictional factors and not selected arbitrarily. In some jurisdictions, tight feasibility constraints may force a high and non-negotiable floor for specificity. In this circumstance, the only options are to either accept a lower floor for sensitivity or invest in a more accurate decision-making strategy (eg, online medical control). This will be more common in jurisdictions with limited resources or with large transport distances. Impact of overtriage may be low in well-resourced metropolitan jurisdictions, allowing specificity requirements to be relaxed. In these jurisdictions, it may be reasonable to proceed with a simple but sensitive screen.
Conclusions
Clinical and technological solutions for the diagnosis of large vessel occlusion may facilitate efficient bypass to endovascular-capable centers. More research is necessary on predictors of treatment eligibility, including time from onset. Jurisdiction-specific features should be considered in the selection and application of bypass selection criteria. 
